Pharmacology complex compound of pro-gly-pro-leu with heparin: hypoglycemic, fibrinolitic and anticoagulant effects in rats with hyperglycemia

Previously it was shown that the use of regulatory peptides of the glyprolin family helps to normalize the hemostasis system and blood glucose levels in experimental resistant hyperglycemia in rats, similar to type 2 diabetes mellitus in humans. It is also known that the anticoagulant heparin inhibits blood coagulation and exhibits a hypoglycemic effect in the body.

The aim of the study is to obtain a complex of the Pro-Gly-Pro-Leu (PGPL) peptide and the unfractionated heparin, to study its effect on glucose and anticoagulant fibrinolytic properties and show its ability to restore the impaired functions of the insular and coagulating blood systems in experimental hyperglycemia in rats.

Materials and Methods. Laboratory Wistar male rats, intact and with experimentally induced hyperglycemia, were used in the experiment. A complex compound of PGPL and heparin was created with a component ratio of 1:1 (mol/mol), which was administered intranasally to hyperglycemic rats once a day for 5 days at the dose of 1 mg/kg. Similarly, the constituent parts of the complex were administrated in equivalent amounts. The anticoagulant activity was determined by the test of activated partial thromboplastin time, fibrinolysis parameters - by tests of total, enzymatic and non-enzymatic fibrinolytic activities, as well as the activity of a tissue plasminogen activator. In addition, blood glucose was measured using special test strips. Results. The use of the PGPL-heparin complex in the animals with hyperglycemia led to normalization of blood glucose levels, an increase in the anticoagulant and fibrinolytic background of blood plasma. These effects persisted for 6 days after the cancellation of the peptide-heparin complex administration to rat.

Conclusion. In the development of experimental hyperglycemia, the PGPL complex with heparin exhibits a combined hypo-glycemic, anticoagulant and fibrinolytic enzymatic and non-enzymatic nature of the effect. In the future, the studied peptide-heparin complex can be used for the prevention and treatment of type 2 diabetes mellitus, complicated by increased blood coagulation.

1. Blair M. Diabetes mellitus review. Urol Nurs. 2016; 36 (1): 27-36. DOI: 10.7257/1053-816X.2016.36.1.27.

2. Ahren B, Schweizer A, Dejager S, Dunning BE, Nillson PM, Persson M, Foley JE. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 2009; 94 (4): 1236-43. DOI: 10.1210/jc.2008-2152.

3. Myasoedov NF, Andreeva LA, Lyapina LA, Ulyanov AM, Shubina TA, Obergan TYu, Pastorova VE, Grigorieva ME. The combined antidiabetogenic and anticoagulation effects of tripeptide Gly-Pro-Arg as estimated in the model of persistent hyperglycemia in rats. Dokl Biol Sci. 2011; 438: 135-7. DOI: 10.1134/S0012496611030057.

4. Shubina TA, Myasoedov NF, Andreeva LA, Lyapina LA, Ulyanov AM, Obergan TY, Pastorova VE. Anticoagulant, fibrinolytic, and hypoglycemic effects of tetrapeptide Arg-Pro-Gly-Pro. Bull Exp Biol Med. 2012; 153 (3): 327-330. DOI: 10.1007/s10517-012-1707-7.

5. Mulukutla SN, Hsu JW, Gaba R, Bohren KM, Guthikonda A, Iyer D, Ajami NJ, Petrosino JF, Hampe CS, Ram N, Jahoor F, Balasubramanyam A. Arginin metabolism is altered in adults with a-в + ketosis-prone diabetes. J Nutr. 2018; 148 (2): 185-93. DOI: 10.1093/jn/nxx032.

6. Brunetta SH, de Camargo CQ, Nunes EA. Does L-leucine supplementation cause any effect on glucose homeostasis in rodent models of glucose intolerance? A systematic review. Amino Acids. 2018; 15: 1663-78. DOI: 10.1007/s00726-018-2658-8.

7. Golla KI, Stavropoulos D, Shields DS, Moran NR. Peptides derived from cadherin juxta membrane region inhibit platelet function. R Soc Open Sci. 2018 Oct 10; 5(10): 172347. DOI:10.1098/rsos.172347.

8. Myasoedov NF, Andreeva LA, Lyapina LA, Shubina TA, Grigor'eva ME, Obergan TYu. Correction of impairments in function of anticoagulation and insular systems of an organism by the regulatory peptide Leu-Pro-Gly-Pro. Biol Bull. 2013; 40 (3): 304-6. DOI: 10.1134/S1062359013030072.

9. Obergan TY, Shubina TA, Grigorieva ME, Lyapina LA, Myasoedov NF, Andreeva LA, Pastorova VE. Uchastie peptida Pro-Gly-Pro-Leu v vosstanovlenii funktsiy protivosvertyvayuschey I insulyarnoy system organizma pri razvitii stoykoy giperglikemii u krys. [Participation of the peptide Pro-Gly-Pro-Leu in restoration of functions anticoagulant and insular organism systems at development by a proof hyperglycemia at rats]. Problems Biol, Med and Pharm Chem. 2013; (4): 38-42. Russian

10. Aster RH. Heparin-induced immune thrombocytopenia - a clinical or laboratory diagnosis? J Thromb Haemost. 2006; 4: 757-8.

11. Lyapina LA, Obergan TY, Pastorova VE. Regulatory role of heparin compounds with low molecular ligands of blood in plasma and thrombocyte hemostasis. Biol Bull. 2011; 38 (2): 165-175. DOI: 10.1134/S1062359011020063.

12. Smolina TYu, Pastorova VE, Lyapina LA. Kompleksoobrazovanie dipeptide prolil-glitsin s geparinom: issledovanie gemostaticheskih svoystv kompleksa in vitro pri vnutrivennom vvedenii. [Complex formation of dipeptide pro-lyl-glycine with heparin; study of haemostatic properties in vitro and after the intravenous injection of complex]. Thrombosis, hemostasis and rheology. 2002; (2): 38-41. Russian

13. Lyapina LA, Myasoedov NF, Andreeva LA, Obergan TY, Shu-bina TA, Grigor'eva ME, Pastorova VE. A complex of heparin with the peptide Arg-Pro-Gly-Pro and its anticoagulative, fibrinolytic, and hypoglycemia effects. Biol Bull. 2012; 39 (1): 60-4. DOI: 10.1134/S1062359012010049.

14. Lyapina LA, Grigorjeva ME, Obergan TY, Shubina TA. Teoreticheskie i prakticheskie voprosy izucheniya funktsional'nogo sostoyaniya protivosvertyvayuschey sistemy krovi. [Theoretical and practical issues in studing the functional state of the anticoagulation system]. M. Advansed Solyushnz. 2012: 160.

15. Dedov II, Shestakova MV, Shestakova OYu. Innovatsii v lechenii sakharnogo diabeta 2 tipa: primenenie inkretinov. [Innovation in the treatment of type 2 diabetes mellitus: use of incretins]. Ter Arkh. 2010; 82 (10): 5-10. PMID: 21341455. Russian.

16. Lyapina LA, Pastorova VE, Samonina GE, Ashmarin IP. The effect of prolil-glycil-proline (PGP) peptide and PGP-rich substances on haemostatic parameters of rat blood. Blood Coagul and Fibrinol. 2000; 11: 409-14.

17. Stief TW. Inhibition of thrombin in plasma by heparin or arginine. Clin Appl Thromb Hemost. 2007; 13 (2): 146-53. DOI: 10.1177/1076029606298987.

18. Myasoedov NF, Rochev DL, Lyapina LA, Obergan TY, An-dreeva LA. Leucine-containing glyprolines (Pro-Gly-Pro-Leu and Leu-Pro-Gly-Pro): participation in hemostatic re-actions in vitro and in vivo in rats with blood coagulation and lipid metabolism disorders. Dokl Biol Sci. 2013; 453: 345-8. DOI: 10.1134/S0012496613060124.

19. Valencia-Mejia E, Batista KA, Fernandes JJA, Fernandes KF. Antihyperglycemic and hypoglycemic activity of naturally occurring peptides and protein hydrolysates from easy-to-cook and hard-to-cook beans (Phaseolus vulgaris). Food Res Int. 2019; 121: 238-46. DOI: 10.1016/j.foodres.2019.03.043.

20. Kvapil M. Strategie a taktika lecby diabetes mellitus 2 Typu. [Strategy and tactics of treatment of type 2 diabetes mellitus]. Vnitr Lek. 2019; 65(4): 273-8. PubMed PMID: 31091946. Czech Republic.